A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
Epistemonikos ID: 21e05663e53aebd809caa0d273a2d70a023b62d2
First added on: May 07, 2024